Galapagos
to webcast Analyst Day on Friday, October 7, 2005
Mechelen,
Belgium and Leiden, The Netherlands; October 3, 2005 –
Galapagos NV (Euronext Amsterdam: GLPGA, Euronext Brussels:
GLPG), invites investors, the media and the general public
to view a live audio webcast of its Analyst Day Meeting
at 10.00 am CET on Friday, October 7, 2005. During the meeting,
Galapagos will present overviews of the company’s
strategy, drug discovery pipeline, and integrated discovery
services. The live audio webcast can be accessed via the
homepage of Galapagos’ website at http://www.glpg.com,
and will be archived and available for replay following
the event. The presentations are expected to last approximately
three hours.
About Galapagos
Galapagos is a publicly traded, genomics-based drug discovery
company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA)
that has successfully discovered and validated novel targets
in the bone and joint diseases - osteoarthritis, osteoporosis
and rheumatoid arthritis, as well as in asthma and Alzheimer’s
disease. Proprietary targets and compounds resulting from
these programs are used for Galapagos’ internal drug
discovery programs, combined with selected out-licensing
and partnering of projects during development. Galadeno,
Galapagos’ partnering unit, provides reagents and
functional screens to leading pharmaceutical, biotech and
nutraceutical companies for rapid identification and validation
of novel drug targets. Galapagos currently employs 78 people,
including 23 PhDs, and occupies facilities in Mechelen,
Belgium, and Leiden, The Netherlands. Galapagos’ partners
include Bayer, Boehringer Ingelheim, Celgene, GlaxoSmithKline,
Novartis, Vertex and Wyeth.
More information about Galapagos and Galadeno can be found
at www.glpg.com.
Contact:
Onno van de Stolpe
CEO Galapagos
Phone: +31 62 909 8028
E-mail: onno@galapagos.be
